upsid driven fx tax rate core
sale beat fx euroimmun organ growth
revenu y/i ahead our/street est
management quot pro forma organ sale growth number core growth
estimate in-lin excl organ contribut euroimmun fx
tailwind sale vs estimate vs estimate
euroimmun organ growth fx tail non-gaap gm
estimate adj opm estimate
larg tie euroimmun strength unfavor fx mix post deal adj
ep vs guid street estimate inclus
net expens lower tax rate vs guid
modest rais fy outlook lot move part
discoveri analyt solut da grew organ led lifesci demand
informat high content screen well solid food environment off-set
soft industri time instrument order diagnost dx legaci core growth
infecti diseas strength mid-teen growth haoyuan tulip
geographi grew asia hsd america europ msd rais
fy guid report revenu organ growth da
legaci dx well yoy euroimmun due fx
fx tailwind legaci biz adj ep guid rais
incl lower tax-rat higher organ growth
overal solid start reiter neutral rate share
rerat trade line peer still bit skeptic
deliv hsd core growth get bullish look see
euroimmun progress traction new vanadi nipt non-invas prenat
test test genom solut busi evolv would
upsid forecast adjust revenu est vs prior
tweak ep estimate vs prior lower po base
in-lin peer peer group multipl compress
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart waltham massachusett
found diversifi
provid scientif instrument consum
servic address basic appli
research well signific global health
safeti issu includ matern fetal health
food safeti environment monitor today
compani oper two segment
environment
diversifi provid
scientif instrument consum servic
think compani tact piec
togeth numer acquir asset sinc
form uniqu comprehens solut
custom nich market posit
portfolio transform improv
growth profil believ compani still
face near-term headwind share
like rang bound
price object base ep estim
in-lin compani broader lst diagnost peer group two year
forward multipl signific premium histor multipl due improv
core growth margin feel multipl appropri given on-going oper
improv improv growth profil compani
upsid risk po better expect organ sale growth margin
expans faster uptak new product capit deploy option
acquisit compani downsid risk competit execut integr risk
weaker macro environ fx swing fund cut slower expect
uptak new product regulatori risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
